Addressing the impact of SARS-CoV-2 infection in persons with congenital bleeding disorders: The Italian MECCOVID-19 study [0.03%]
意大利MECCOVID-19研究：针对先天性出血性疾病患者SARS-CoV-2感染的影响
Antonella Coluccia,Emanuela Marchesini,Anna Chiara Giuffrida et al.
Antonella Coluccia et al.
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden: A report from the Swedish national registry for bleeding disorders [0.03%]
瑞典国家出血性疾病登记处的Fc融合重组FVIII预防使用的真实世界研究报告
Margareta Holmström,Elsa Olsson,Jan Astermark et al.
Margareta Holmström et al.
Clinical and ultrasound evaluation of patients with haemophilia on prophylaxis [0.03%]
接受预防治疗的血友病患者的临床和超声影像评估
Carla Daffunchio,Gustavo Galatro,Martín Rossi et al.
Carla Daffunchio et al.
Introduction: Primary prophylaxis is the current gold standard in haemophilia care for the prevention of bleeding and ensuing joint damage. Early detection of joint bleeding, whether symptomatic or subclinical, preferably...
Inherited bleeding disorders in Afghanistan: The current situation amid COVID-19 [0.03%]
阿富汗新冠肺炎疫情期间的遗传性出血性疾病患者的现状
Sayed Hamid Mousavi,Shohra Qaderi,Attaullah Ahmadi et al.
Sayed Hamid Mousavi et al.
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A [0.03%]
单个受试者与人群基础的药动学对比研究优化A型血友病患者使用司妥氯octocog预防治疗
Jan Astermark,Anna Olsson,Pierre Chelle et al.
Jan Astermark et al.
Introduction: The use of pharmacokinetic assessment for optimal prophylactic dosing of factor concentrates in haemophilia has gained increasing enthusiasm over the last decade. However, blood sampling on several occasions...
Robert F Sidonio Jr,Glaivy Batsuli
Robert F Sidonio Jr
A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis [0.03%]
一种针对病态接受的介入改善了血友病成人预防治疗的依从性和生活质量
Johanna Wilhelmina Hoefnagels,Kathelijn Fischer,Ruud A T Bos et al.
Johanna Wilhelmina Hoefnagels et al.
Introduction: Adherence to prophylactic treatment (prophylaxis) in persons with haemophilia is challenging and has been reported at only ±50%. Acceptance problems are one of the main reasons for non-adherence in haemophi...
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B [0.03%]
人凝血因子IX相似药治疗乙型血友病成人患者的效果和安全性
Johnny Mahlangu,Howard Levy,Martin Lee et al.
Johnny Mahlangu et al.
Aim: Phase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28 days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB). ...
Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A [0.03%]
长效重组F VIII制品治疗A型血友病关键研究的比较分析
Pier Mannuccio Mannucci,Paolo Angelo Cortesi,Matteo Nicola Dario Di Minno et al.
Pier Mannuccio Mannucci et al.
The need to reduce the burden of injections, and improve adherence and clinical outcomes in haemophilia A led to the development of recombinant FVIII products endowed with an extended plasma half-life (EHL-rFVIII) in comparison with standar...
The SLIM study-Shared medical appointments to change lifestyles of overweight people with haemophilia: A randomized multiple baseline (n-of-1) design [0.03%]
SLIM研究——联合门诊改变血友病超重患者的生活方式：一项随机多基线（N=1）设计的研究
Marcel A L Hendriks,Johanna W M van Wanroij,Britta A P Laros-van Gorkom et al.
Marcel A L Hendriks et al.
Introduction: People with haemophilia suffer from haemophilic joint disease that may result in physical inactivity and overweight. Shared medical appointments (SMAs) might help limit the consequences of haemophilic arthro...
Randomized Controlled Trial
Haemophilia : the official journal of the World Federation of Hemophilia. 2021 Jul;27(4):606-617. DOI:10.1111/hae.14306 2021